![]() Survival estimates from the time of diagnosis incorporating known disease- and host- specific risk factors are the basis for myeloma risk stratification systems. ![]() Multiple myeloma (MM) is a plasma cell disorder characterized by marked heterogeneity in terms of clinical, cytogenetic, and molecular disease characteristics which is reflected in varying prognosis for individual patients. The prognostic impact of high-risk cytogenetic factors decreased with additional years survived. Among MM patients, 5-year CS was stable at 1–5 years from diagnosis. Chromosome 17 abnormality was associated with decreased survival only at 1 year. The adverse impact of 1q gain/amplification, high-risk IgH translocation, and ISS-3 was significant at 1 and 3 years but not 5 years. On multivariate analysis, age ≥ 65 and proteasome inhibitor+immunomodulatory-based induction were associated with decreased survival and increased survival, respectively, retained at 5 years. Median follow-up was 6.2 years and median overall survival from diagnosis was 7.5 years. CS ( t | s) was defined as the probability of surviving t years given survival of s years. This is a retrospective study including 2556 MM patients diagnosed between 20. ![]() This study was conducted to estimate CS at 1–8 years from diagnosis and the impact of baseline prognostic factors on CS in multiple myeloma (MM) patients. Conditional survival (CS) provides dynamic survival predictions over time. Overall survival estimates from diagnosis are valuable for guiding treatment, but do not consider the years already survived. Conditional survival in multiple myeloma and impact of prognostic factors over time ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |